Label-free nanoplasmonic sensing of tumor-associate autoantibodies for early diagnosis of colorectal cancer.
Colorectal cancer is treatable and curable when detected at early stages. However there is a lack of less invasive and more specific screening and diagnosis methods which would facilitate its prompt identification. Blood circulating autoantibodies which are immediately produced by the immune system at tumor appearance have become valuable biomarkers for preclinical diagnosis of cancer. In this work, we present the rapid and label-free detection of colorectal cancer autoantibodies directly in blood serum or plasma using a recently developed nanoplasmonic biosensor. Our nanoplasmonic device offers sensitive and real-time quantification of autoantibodies with excellent selectivity and reproducibility, achieving limits of detection around 1 nM (150-160 ng mL(-1)). A preliminary evaluation of clinical samples of colorectal cancer patients has shown good correlation with ELISA. These results demonstrate the reliability of the nanobiosensor strategy and pave the way towards the achievement of a sensitive diagnostic tool for early detection of colorectal cancer.
Nanobiosensors and Bioanalytical Applications Group (NanoB2A), Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, 08193, Barcelona, Spain; CIBER-BBN Networking Center on Bioengineering, Biomaterials and Nanomedicine, Spain.
Maria
M
Soler
CIBER-BBN Networking Center on Bioengineering, Biomaterials and Nanomedicine, Spain; Nanobiosensors and Bioanalytical Applications Group (NanoB2A), Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, 08193, Barcelona, Spain. Electronic address: mcarmen.estevez@cin2.es.
M-Carmen
MC
Estevez
Functional Proteomics Group, Centro de Investigaciones Biológicas (CIB-CSIC), 28040, Madrid, Spain.
Roi
R
Villar-Vazquez
Functional Proteomics Group, Centro de Investigaciones Biológicas (CIB-CSIC), 28040, Madrid, Spain.
J Ignacio
JI
Casal
Nanobiosensors and Bioanalytical Applications Group (NanoB2A), Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, 08193, Barcelona, Spain; CIBER-BBN Networking Center on Bioengineering, Biomaterials and Nanomedicine, Spain.
Laura M
LM
Lechuga
D001323:Autoantibodies / Q000096:biosynthesis*; D014408:Biomarkers, Tumor / Q000097:blood; D015179:Colorectal Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000276:immunology; D055088:Early Detection of Cancer; D006801:Humans; D057230:Limit of Detection; D036103:Nanotechnology / Q000295:instrumentation*
D001323:Autoantibodies; D014408:Biomarkers, Tumor
Autoantibodies; Clinical diagnosis; Colorectal cancer; Nanoplasmonic biosensor; Plasma; Serum